These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12416052)

  • 21. HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--US, 1998-2003.
    Ann Pharmacother; 2005 Nov; 39(11):1967-8. PubMed ID: 16219891
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?
    Moore MR; Whitney CG
    Clin Infect Dis; 2008 Jan; 46(2):183-5. PubMed ID: 18171248
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination.
    Rückinger S; von Kries R; Reinert RR; van der Linden M; Siedler A
    Vaccine; 2008 Jul; 26(32):3984-6. PubMed ID: 18495301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
    Pletz MW; Maus U; Krug N; Welte T; Lode H
    Int J Antimicrob Agents; 2008 Sep; 32(3):199-206. PubMed ID: 18378430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Declining invasive pneumococcal disease in the U.S. elderly.
    McBean AM; Park YT; Caldwell D; Yu X
    Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreasing invasive pneumococcal disease in the elderly: a state-level analysis.
    McBean AM; Jung K; Hebert PL
    Vaccine; 2006 Jul; 24(27-28):5609-14. PubMed ID: 16725240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].
    van Furth AM; Vandenbroucke-Grauls CM
    Ned Tijdschr Geneeskd; 2002 May; 146(20):932-3. PubMed ID: 12051059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal serotypes in the elderly.
    Kellner JD; Mandell L
    Clin Infect Dis; 2005 Aug; 41(4):488-9. PubMed ID: 16028156
    [No Abstract]   [Full Text] [Related]  

  • 32. [Survey on vaccination strategies used in different Italian Regions, for the 7-valent conjugate pneumococcal, meningococcal C and varicella vaccines].
    D'Ancona F; Alfonsi V; Ciofi degli Atti ML
    Ig Sanita Pubbl; 2006; 62(5):483-92. PubMed ID: 17206224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?
    Giele C; Moore H; Bayley K; Harrison C; Murphy D; Rooney K; Keil AD; Lehmann D
    Vaccine; 2007 Mar; 25(13):2379-84. PubMed ID: 17064825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2006 May; 32(ACS-4):1-6. PubMed ID: 16718922
    [No Abstract]   [Full Text] [Related]  

  • 35. [Streptococcus pneumoniae infection in a health district of Pamplona (Spain)].
    Viguria Sánchez N; Bernaola Iturbe E; Herranz Aguirre M; Torroba Alvarez L; Gil-Setas A
    An Esp Pediatr; 2002 Oct; 57(4):380-1. PubMed ID: 12392678
    [No Abstract]   [Full Text] [Related]  

  • 36. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine.
    Hendrickson DJ; Blumberg DA; Joad JP; Jhawar S; McDonald RJ
    Pediatr Infect Dis J; 2008 Nov; 27(11):1030-2. PubMed ID: 18845981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of pneumococcal conjugate vaccine in Greater Vancouver, Canada: 2004-2005.
    Bjornson G; Scheifele DW; Bettinger J; Patrick DM; Gustafson L; Daly P; Tyrrell GJ
    Pediatr Infect Dis J; 2007 Jun; 26(6):540-2. PubMed ID: 17529875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expected benefits of pneumococcal vaccination in Canadian infants and children < 5 years old.
    Can Commun Dis Rep; 2006 Mar; 32(5):45-54. PubMed ID: 16649291
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pneumococcal disease and emergence of serotypes in the vaccine era. Transient trends and serotype replacement?].
    Moraga-Llop FA
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):1-4. PubMed ID: 19217995
    [No Abstract]   [Full Text] [Related]  

  • 40. Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine.
    Carstairs KL; Tanen DA; Johnson AS; Kailes SB; Riffenburgh RH
    Ann Emerg Med; 2007 Jun; 49(6):772-7. PubMed ID: 17337092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.